

anthrax protective antigen binding protein, wherein the molar ratio of protective antigen to the full length protein bound to the anthrax protective antigen binding protein is greater than one.

2. (once amended) The composition of claim 1 wherein the protective antigen is a processed protective antigen.

3. (once amended) The composition of claim 1 wherein the composition is sterile.

4. (once amended) The composition of claim 1 wherein the composition further comprises physiologically compatible salts.

5. (once amended) The composition of claim 4 wherein the composition is in an aqueous solution of physiologically compatible salts.

6. (once amended) The composition of claim 1 wherein the anthrax protective antigen binding protein is the lethal factor of *Bacillus anthracis*.

7. (once amended) The composition of claim 1 wherein the anthrax protective antigen binding protein comprises at least about the first 250 amino acid residues of the lethal factor of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor.

REMARKS

With this amendment, claims 1-7 are pending in the application, and claims 8-28 have been canceled.

*1. The invention*

The present application relates to methods of using binary bacterial toxins to deliver whole proteins to the cytosolic MHC class I processing pathway. The *Bacillus anthracis* binary toxin is one example of such a binary toxin. This toxin consists of two